Ashley V. DiMarco

Supplementary Figure S4 from RIT1M90I Is a Driver of Lung Adenocarcinoma Tumorigenesis and Resistance to Targeted Therapy

Ashley V. DiMarco, Mirunalini Ravichandran, Jeffrey Lau, Anthony Lima et autres

Supplementary Figure S4: (A) NCI-H358-RIT1M90I cells are resistant to divarasib single agent treatment and can be re-sensitized with divarasib and migoprotafib combination both in vitro and in vivo.

Supplementary Figure S3 from RIT1M90I Is a Driver of Lung Adenocarcinoma Tumorigenesis and Resistance to Targeted Therapy

Ashley V. DiMarco, Mirunalini Ravichandran, Jeffrey Lau, Anthony Lima et autres

Supplementary Figure S3: Human RIT1 cell line, NCI-H2110, is sensitive to migoprotafib, belvarafenib, cobimetinib as single agent and in combination in vitro and in vivo.

Supplementary Figure S2 from RIT1M90I Is a Driver of Lung Adenocarcinoma Tumorigenesis and Resistance to Targeted Therapy

Ashley V. DiMarco, Mirunalini Ravichandran, Jeffrey Lau, Anthony Lima et autres

Supplementary Figure S2: Ex vivo RIT1 cell lines have Trp53 genetic knockout and therapeutic vulnerabilities include MAPK/PI3K inhibitors and statins.

Supplementary Figure S1 from RIT1M90I Is a Driver of Lung Adenocarcinoma Tumorigenesis and Resistance to Targeted Therapy

Ashley V. DiMarco, Mirunalini Ravichandran, Jeffrey Lau, Anthony Lima et autres

Supplementary Figure S1: RIT1 tumors have heterogenous pERK expression.

Supplementary Table S1 from RIT1M90I Is a Driver of Lung Adenocarcinoma Tumorigenesis and Resistance to Targeted Therapy

Ashley V. DiMarco, Mirunalini Ravichandran, Jeffrey Lau, Anthony Lima et autres

Supplementary Table S1: Assessment of immunohistochemistry staining intensity on lungs from RIT1 mice. Pathological findings are summarized for all tumors within each animal. Localization of CD3-positive T cells is described. IHC staining intensity is qualitatively scored as +++; strongly positive, +/-; mixed …

Data from RIT1M90I Is a Driver of Lung Adenocarcinoma Tumorigenesis and Resistance to Targeted Therapy

Ashley V. DiMarco, Mirunalini Ravichandran, Jeffrey Lau, Anthony Lima et autres

Abstract RIT1 is a RAS-family guanosine triphosphatase that is mutated in 2.4% and amplified in up to 14% of patients with lung adenocarcinoma. Yet the oncogenic potential of RIT1 in the lungs has not been fully established. Consequently, patients with RIT1 alterations …

RIT1M90I Is a Driver of Lung Adenocarcinoma Tumorigenesis and Resistance to Targeted Therapy

Ashley V. DiMarco, Mirunalini Ravichandran, Jeffrey Lau, Anthony Lima et autres

RIT1 is a RAS-family guanosine triphosphatase that is mutated in 2.4% and amplified in up to 14% of patients with lung adenocarcinoma. Yet the oncogenic potential of RIT1 in the lungs has not been fully established. Consequently, patients with RIT1 alterations are …

fr, ca, us (code pays fourni par la source)

Data from APOBEC3 Activity Promotes the Survival and Evolution of Drug-Tolerant Persister Cells during EGFR Inhibitor Resistance in Lung Cancer

Nina Marie G. Garcia, Jessica N. Becerra, Sharan Srinivasan, Brock J. McKinney et autres

Abstract APOBEC mutagenesis is one of the most common endogenous sources of mutations in human cancer and is a major source of genetic intratumor heterogeneity. High levels of APOBEC mutagenesis are associated with poor prognosis and aggressive disease across diverse cancers, but …

Supplementary File 2 from APOBEC3 Activity Promotes the Survival and Evolution of Drug-Tolerant Persister Cells during EGFR Inhibitor Resistance in Lung Cancer

Nina Marie G. Garcia, Jessica N. Becerra, Sharan Srinivasan, Brock J. McKinney et autres

GSEA results showing gene sets enriched in A3B-expressing cells (on_NR) compared to cells not expressing A3B (off_NR).

Supplementary File 1 from APOBEC3 Activity Promotes the Survival and Evolution of Drug-Tolerant Persister Cells during EGFR Inhibitor Resistance in Lung Cancer

Nina Marie G. Garcia, Jessica N. Becerra, Sharan Srinivasan, Brock J. McKinney et autres

Trinucleotide contexts of mutations in gefitinib-sensitive and gefitinib-resistant PC9 cells with and without A3B expression.

Figure 3 from APOBEC3 Activity Promotes the Survival and Evolution of Drug-Tolerant Persister Cells during EGFR Inhibitor Resistance in Lung Cancer

Nina Marie G. Garcia, Jessica N. Becerra, Sharan Srinivasan, Brock J. McKinney et autres

APOBEC3B expression alters the evolutionary trajectory of acquired resistance to EGFR inhibitors. A, Kinetics of evolution of gefitinib resistance in PC9 cells with or without A3B expression. B, Representative dose–response curves to gefitinib for sensitive and resistant A3B-off and A3B-on PC9 cells. …

Figure 2 from APOBEC3 Activity Promotes the Survival and Evolution of Drug-Tolerant Persister Cells during EGFR Inhibitor Resistance in Lung Cancer

Nina Marie G. Garcia, Jessica N. Becerra, Sharan Srinivasan, Brock J. McKinney et autres

Engineering an inducible system for APOBEC3B expression in PC9 cells. A, qRT-PCR analysis showing A3A and A3B expression in PC9 cells following treatment with gefitinib or osimertinib over the course of 14 days. Error bars represent SEM of three technical replicates. Veh, …